

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/105596 A1

- (51) International Patent Classification⁷: **A23K 1/00**, 1/18, A23L 1/03, A61K 35/74
- (74) Agents: **FORD, Timothy, James** et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).
- (21) International Application Number: PCT/GB03/02469
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 6 June 2003 (06.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0212975.7 6 June 2002 (06.06.2002) GB
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **MARS, INCORPORATED** [US/US]; 6885 Elm Street, McLean, VA 22101 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **BAILLON, Marie-Louise, Amanda** [GB/GB]; Waltham Centre for Pet Nutrition, Waltham-on-the-Wolds, Leicestershire LE14 4RT (GB). **BUTTERWICK, Richard, Fulton** [GB/GB]; Waltham Centre for Pet Nutrition, Freeby Lane, Waltham-on-the Wolds, Leicestershire LE14 4RT (GB).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MAMMALIAN ANIMAL COMPOSITON

(57) Abstract: The present invention relates to the use of a probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal *Campylobacter* infection in a mammalian animal.

WO 03/105596 A1

11 PRTS

Mammalian Animal Composition

5 The present invention relates to the use of a probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal *Campylobacter* infection in a mammalian animal.

15 Companion animals, particularly dogs and cats, are significant vectors of non-food borne gastrointestinal infection. Decreasing the risk of infection of these animals, and the ability to reduce infection when it does occur plays an important role in reducing zoonotic risk. Zoonotic risk is the risk of transfer of infection from one species to another. Clearly, this includes the risk of transfer of infection from companion animals to humans.

20 In dogs and cats, *Campylobacter* and *E. coli* are the predominant gastrointestinal pathogens, causing both clinical and non-clinical infections.

In dogs and cats, faecal shedding of *Campylobacter* occurs in animals which are infected, whether clinical symptoms are shown or not.

25 *Campylobacter* is a most common zoonoses, as well as being a common cause of gastroenteritis in humans. It is estimated that 5% of all human *C. jejuni*-induced enteritis result from exposure to infected dogs or cats.

30 In view of the zoonotic risk of *Campylobacter* infection from companion animals to humans, it is recommended that control measures that should be considered, which

include restricting contact of children with puppies which may be infected, pets which may be infected be kept away from food preparation areas, affected animals should be kept apart from healthy ones and thorough disinfecting of bedding, food bowls etc should be carried out.

5

As mentioned above, *Campylobacter* infection in cats and dogs may or may not result in clinical symptoms. Thus it is difficult to know whether any animal, at any time, is infected or not. A 3 to 7 day incubation period is found in dogs and cats, which may be followed by a diarrhoea that ranges from mild to transient to mucus laden bloody diarrhoea. However, since diarrhoea is symptomatic of an enormous number of problems, including a range of infections, dietary problems (rapid change, over eating, scavenging, food tolerance, food hypersensitivity), neoplasia, inflammatory bowel disease, pancreatitis, metabolic disease, systemic disease, and drug reactions, the noting of diarrhoea in itself cannot be used to diagnose *Campylobacter* infection.

15

Accordingly, it would be of benefit to provide means to reduce or prevent *Campylobacter* infection in the gastrointestinal tract, particularly of companion animals. A benefit is to reduce or prevent *Campylobacter* infection, without the need for a formal diagnosis of *Campylobacter* infection. A benefit of reducing or preventing *Campylobacter* infection in mammalian animals results in a reduction or prevention of shedding of *Campylobacter* in faeces and thus reduces or prevents the zoonotic risk, particularly to humans.

20

Accordingly, the present invention provides the use of a probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal.

25

A probiotic microorganism is one which can help to promote a healthy intestinal tract. Probiotic microorganisms beneficially affect a host by improving the microbial balance.

30

The prevention or reduction of gastrointestinal *Campylobacter* infection results not only in a reduced presence of *Campylobacter* in the GI tract, but also, and importantly, reduces or prevents shedding of *Campylobacter* in faeces. Reduction of the shedding of *Campylobacter* in faeces is a significant factor in reducing or preventing the transfer of *Campylobacter* infection from animal to animal, including from companion animal to humans.

The probiotic microorganism may be any which is known, including one or more from the following:-

Lactobacillus (such as *murinus*, *ruminus*, *ramnosis*, *acidophilus*, *reuteri* or *mucosae*), *Bifidobacterium*, *Bacterioides*, *Aostridium*, *Fusobacterium*, *Melissococcus*, *Propionibacterium*, *Streptococcus*, *Enterococcus*, *Lactococcus*, *Staphylococcus*, *Peptostrepococcus*, *Bacillus*, *Pediococcus*, *Micrococcus*, *Leuconostoc*, *Weisella*, *Aerococcus*, *Oenococcus* and *Eubacterium*.

Typically, the *Campylobacter* infection will be *Campylobacter jejuni*. This is the most significant strain in humans which causes gastroenteritis. The *Campylobacter* infection may be any other, including *Campylobacter coli*, *C. upsaliensis*, *C. lari*, *C. fetus*, *C. rectus* and/or *C. hyointestinalis*.

The mammalian animal according to the present invention may be any. Preferably, the mammalian animal is a companion animal, such as the domestic dog or the domestic cat. In the present invention, the terms domestic dog and domestic cat mean dogs and cats, in particular *Felis domesticus* and *Canis domesticus*. The present invention also applies to humans.

The composition for the prevention or reduction of gastrointestinal *Campylobacter* infection may be any composition which a mammalian animal may take. Preferably it

is a composition which any mammalian animal may consume in its diet. Thus, the invention covers standard food products as well as food snacks. The composition may comprise a cereal product or confectionery, such as snack bars, biscuits and sweet products, including candy and chocolate.

5

When the mammalian animal is a companion animal (a pet animal) the composition may encompass any product which a pet may consume, in particular in its diet. The composition is preferably a dry pet food. Such dry pet foods include dry kibbles comprising a cooked starch source.

10

The foodstuff may be a cooked product. It may incorporate meat or animal derived materials (such as beef, chicken, turkey, lamb, blood plasma, marrowbone etc or two or more thereof). The composition may alternatively be meat-free (preferably including a meat substitute such as soya, maize gluten or a soya product). The composition may contain additional protein sources such as soya protein concentrate, milk proteins, gluten etc. The composition may contain a starch source such as one or more grains (e.g. wheat, corn, rice, oats, barley etc) or may be starch-free. A typical dry commercial dog and cat food contains about 30% crude protein, about 10-20% fat and the remainder being carbohydrate, including dietary fibre and ash. A typical wet or moist product contains (on a dry matter basis) about 40% fat, 50% protein and the remainder being fibre and ash. The present invention is particularly relevant for a composition as hereindescribed which is sold as a diet, foodstuff or supplement for a cat or dog.

20

25

Further, the composition may be a foodstuff in the form of one or more of a cereal product, energy bar, breakfast cereal, confectionery, medicament, food supplement or a drink. The supplement may be in the form of a dried powder, tablet, capsule, liquid or gel.

30

The probiotic microorganism may be in any form, for example in a powdered dry form

or in spore form (for the microorganisms which form spores). The probiotic may be encapsulated in order to protect it from moisture. In addition, the probiotic microorganism may have undergone processing in order for it to increase its survival in any processing. Accordingly, the microorganism may be coated or encapsulated in
5 a polysaccharide, fat, starch, protein or in a sugar matrix. The probiotic microorganism may be in a coating (outer or a layer), or a filling, or it may be admixed throughout the composition.

It may be preferable to avoid the probiotic being in contact with flour as flour contains
10 enzymes which may adversely affect the viability of the probiotic. Standard encapsulation techniques known in the art can be used, and for example, as discussed in US 6,190,591 (which is incorporated by reference herein).

The composition according to the first aspect of the invention may comprise the
15 probiotic microorganism in any concentration, preferably at a concentration of from 10^3 to 10^{15} viable cells per gram of the total composition. This concentration of cells provides a suitable concentration for successful colonisation of the gastrointestinal tract and providing the optimum health benefits to the animal. An additional probiotic strain may be present at a concentration of from 10^3 to 10^{15} viable cells per gram of
20 the total composition.

According to a second aspect, the present invention provides a method for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal, the method comprising the administration of a probiotic microorganism to said
25 animal.

Preferably, the probiotic microorganism is comprised in a composition, for example as described above in relation to the first aspect of the invention.

30 All preferred features of the first aspect of the invention, also apply to the second.

In the method of the second aspect of the invention, the animal is preferably in need of the prevention or reduction of gastrointestinal *Campylobacter* infection.

- 5 The administration of the probiotic microorganism may be by any means or preferably the administration is oral administration (i.e. ingestion).

10 A third aspect of the present invention provides a probiotic microorganism for use in preventing or reducing gastrointestinal *Campylobacter* infection in a mammalian animal.

All preferred features of the first and second aspect of the invention, also apply to the third.

- 15 The present invention is described with reference to the figures. Wherein, Figure 1: Faecal bacteria counts by Fluorescent *in-situ* hybridization (FISH): *Campylobacter* as a % of total population. Showing post-antibiotic (baseline) levels compared to effect of probiotic +/- supplementation for 10 days or 23 days.

- 20 The present invention will now be described with reference to the following non-limiting examples:

Example 1

- 25 Animal details and husbandry conditions

Cats (n=48) housed in catcare 6 were selected for the study (table 1). Catcare 6 had recently been diagnosed with a clinical naturally acquired *Campylobacter* infection. The cats were group housed at all times and had constant access to fresh water.

Four rooms were selected to undergo probiotic +/- treatment.

5 In the 10 days prior to the beginning of the probiotic trial, all cats were treated with antibiotics to control the clinical *Campylobacter* infection. All cats received Ceporex (1 tablet twice daily for 10 days). Ceporex contains 50mg cephalexin, a 3rd generation cephalosporin antibiotic.

Feeding regimen

10 All cats were group fed according to a standard protocol. Large trays of food containing 400g/cat, being offered once daily at 2pm and left down overnight. The diet was standard canned Whiskas Beef (chunk in loaf).

Probiotic dosing regimen

15 Cats in the probiotic + treatment groups (rooms 1 and 2) were orally dosed with 10mg (1×10^9 cells) of a freeze-dried preparation of *Lactobacillus acidophilus*. Deposited under Accession No. NCIMB 41117 once daily after feeding, administered in a gelatin capsule. The probiotic - groups (rooms 11 and 12) received no capsule.

20 Dosing commenced immediately after the cessation of antibiotic therapy and continued for 27 days.

Study design

25 The study was designed to incorporate measures at key points during the process of antibiotic treatment and recovery. The measures taken were:

- Group daily food intakes.

- Weekly bodyweight.
- Group faeces quality.
- Bacterial counts by agar culture and FISH.
- Bacterial profiling by API biochemical fingerprinting and ribotyping.

5

Methodology

Food intakes

- 10 Daily food consumption was monitored for each room, being the amount offered minus that refused. Individual food intakes are not available for this study.

Faeces Quality

- 15 Group faeces quality was assessed daily using the Waltham Faeces Scoring GuidelinesTM. Each defecation was graded on a subjective, 17 point scale. Individual faeces scores are not available for this study.

Faecal Bacteria profile

20

Faeces voided overnight were discarded. Every defecation voided between 8am and 4pm was collected into a clean faeces collection pot and used for bacteriological examination. Faeces were processed immediately in the laboratory under appropriate incubation conditions.

25

The following bacterial groups were quantified using selective agars:

- Anaerobic culture of *Lactobacilli* on MRSa agar (Oxoid)
- Micro-aerobic culture of *Campylobacter* on selective agar (LabM)

In addition, the following bacterial groups were quantified by fluorescence *in situ* hybridisation (FISH):

- 5
- *Clostridia*
 - *Lactobacilli*
 - *Campylobacter*

10

Methodology for *Campylobacter* enumeration using selective agar

A swab of faeces was spread onto a plate and incubated micro-aerobically (5% O₂), selecting for single colonies. This method is qualitative and does not provide quantitative information.

15

Statistical Analysis

Data were analysed using multifactor ANOVA, with antioxidant supplementation +/- as the second factor and students t test, as appropriate. $P < 0.05$ was considered significant.

20

Results

Faecal bacteria

Plate Counts

25

Lactobacilli were enumerated on three occasions during the study:

- towards the end of antibiotic therapy
- following 10 days +/- probiotic treatment
- following 23 days +/- probiotic treatment

Total *Lactobacilli* in faeces were enumerated using de Man, Rogosa, Sharpe (MRS) agar acidified to a pH of 5.0. There was no significant effect of probiotic treatment on absolute numbers of *Lactobacilli* at any time point.

5

Campylobacter were enumerated on four occasions during the study:

- before the start of antibiotic therapy
- towards the end of antibiotic therapy
- following 10 days +/- probiotic treatment
- following 23 days +/- probiotic treatment

10

Table 1: % of faeces samples that tested positive for *Campylobacter* using selective agar.

Campylobacter (log ₁₀)	Probiotic +		Probiotic -	
	% positive	n	% positive	n
Pre-antibiotic	100	12	100	12
Post antibiotic	50	12	67	12
10 days +/- probiotic	67	12	100	11
23 days +/- probiotic	88	17	100	15

15

This method is qualitative and merely indicates the presence or absence of *Campylobacter* in faeces samples. Prior to antibiotic therapy, all faeces samples cultured tested positive for *Campylobacter*, although this was decreased to 59% (overall) by antibiotic therapy. Following 10 days probiotic +/- supplementation, 100% of faeces from the probiotic - group tested positive for *Campylobacter*, but this was decreased to 67% in the probiotic + group. Following 23 days probiotic +/- supplementation, 100% of faeces from the probiotic - group tested positive for *Campylobacter*, but this was decreased to 88% in the probiotic + group (Table 1).

20

Probiotic supplementation therefore decreased the prevalence of *Campylobacter* positive faeces. Re-infection rates were also reduced in the probiotic + group with 67% of faecal samples testing positive for *Campylobacter* ten days post treatment, compared to 100% of faeces from the probiotic - group. These findings indicate strength resistance of healthy cats to infection with *Campylobacter* species following supplementation with *Lactobacilli acidophilus* (Accession No. NCIMB 41117).

Fluorescence in situ hybridisation

Enumeration of *Clostridia*, *Lactobacilli* and *Campylobacter* by FISH was conducted on four occasions during the study:

- before the start of antibiotic therapy
- towards the end of antibiotic therapy
- following 10 days +/- probiotic treatment
- following 23 days +/- probiotic treatment

Bacterial counts (% total population) are given in Table 2 for *Campylobacter* and shown graphically in figure 1.

There was no significant effect of probiotic supplementation on *Lactobacilli* as a % of the total population or absolute numbers (\log_{10}) at any time during the study.

There was a significant difference between probiotic +/- groups in *Clostridia* (as a % of the total population as well as a small (less than one \log_{10}) but significant ($p=0.007$) difference in absolute numbers) prior to the beginning of antibiotic therapy. This difference between groups was, however, eliminated by the antibiotic therapy such that at baseline both groups were similar. Administration of probiotics significantly decreased *Clostridia* (as % of total population) at both 10 and 23 days. This decrease was not reflected in absolute numbers of *Clostridia*, although at 23 days there was a

small (less than one \log_{10}) although significant ($p=0.006$) difference between the probiotic +/- groups.

There was no difference in *Campylobacter* between the groups at baseline. At 10 days +/- probiotic supplementation, *Campylobacter* (as % total population) had increased in all 4 groups (figure 1). However, *Campylobacter* (as % of total population) was significantly reduced in probiotic treated animals compared to negative controls at 10 days (table 2, figure 1). Following 23 days probiotic supplementation *Campylobacter* (as % total population) was decreased compared to baseline, but was increased compared to baseline in those animals that did not receive probiotics. At 23 days *Campylobacter* (as % of total population) was significantly lower in probiotic treated animals compared to negative controls (table 2, figure 1). This was reflected in absolute numbers at 23 days, with a small (less than one \log_{10}) but significant difference between groups.

Table 2: Faecal bacteria counts by FISH: *Campylobacter* as a % of total population.

Campylobacter	Probiotic +			Probiotic -			Significance of difference
	mean	SD	n	mean	SD	n	
Pre-antibiotics	14.27	4.92	11	14.48	4.15	10	0.727
Post-antibiotics	6.14	3.83	10	5.25	2.3	12	0.494
10 days treatment	12.2	4.2	12	19.7	9.2	11	0.02
23 days treatment	3.94	2.58	17	14.06	10.0	11	0.001

Probiotic supplementation resulted in little difference in *Lactobacilli* compared to control animals, as measured by both plate and FISH methodology. This finding is unusual in relation to previous findings, when probiotics have been shown to increase the number of beneficial *Lactobacilli*, and may be due to the compromised health status of the cats in the current study. These cats all had a

clinical infection of *Campylobacter* prior to the beginning of the trial and this would be expected to adversely affect the normal microflora of all cats.

- ◇ As can be seen, antibiotics decreased the *Campylobacter* (as a percentage of the total population of faecal bacteria) from 14.38 to 5.69% ($P < 0.05$, paired T test).
5 At two weeks, *Campylobacter* levels had risen in both groups, however, the rise in the probiotic + group was significantly less than in the probiotic – group (12.2 and 19.7% of total population, respectively, $P < 0.05$). Although the organism count decreased in both groups at four weeks, elimination from the probiotic + group cats was markedly accelerated (14.06% of total population in probiotic – and 3.94% of total population in probiotic + cats, $P < 0.05$).
10
- ◇ Probiotic supplementation significantly decreased the levels of potentially pathogenic *Campylobacter* compared to cats that had received no probiotics.
- ◇ The study described herein demonstrates that *Lactobacillus acidophilus* can improve recovery of the feline gastrointestinal tract from the effects of antibiotic therapy, by decreasing the number of *Campylobacter* as a % of the total population. This would be expected to decrease recovery time of the cat and therefore decrease the zoonotic risk from faecal shedding of *Campylobacter*.
15

Example 2

20

Determination of the Anti-Campylobacter Activity of Probiotic Microorganism

OBJECTIVE

- 25 In this study, the ability of potential probiotic strains of bacteria to have an antibacterial effect on *Campylobacter jejuni* is addressed.

MATERIALS AND METHODS

Bacterial strains and culture conditions

5 *Campylobacter jejuni* cultures were maintained on Mueller Hinton agar (Oxoid) and used as an inoculum for liquid cultures (Mueller Hinton broth, Oxoid) that were grown in 20ml volumes in 50ml conical flasks shaken on an orbital shaker.

10 Potential probiotic strains were maintained on MRS agar and cultured in 20ml volumes in MRS broth under anaerobic conditions.

Experimental set-up

15 (i) Liquid cultures of probiotic strains were set up and incubated overnight under appropriate conditions. A 1µl loopful of the overnight culture was then used to inoculate the very centre of a 150mm MRS agar plate. These large plates were incubated anaerobically overnight to allow the growth from the spot inoculum.

20 (ii) Pathogenic liquid cultures were set up on the same day as the probiotic spot cultures and incubated overnight. Overnight pathogen cultures were adjusted to A_{600} 0.4 before inclusion in the assay.

25 (iii) To 15ml of molten MH agar, 200µl of the adjusted pathogen culture was added and swirled gently to mix. This agar/pathogen mix was then poured into a 90mm petri dish and allowed to set.

30 (iv) When pathogen inoculated agar set it was aseptically removed from the petri dish. Two sterile disposable loops were used to remove the agar by gently lifting it away from the dish and slowly lowering the agar disc onto the spot of probiotic growth on the 150mm agar plates.

- (v) The agar "sandwich" was incubated overnight at 37°C under aerobic conditions.
- 5 (vi) After overnight incubation, the zone of no bacterial growth over the probiotic spot was measured and the diameter of the probiotic spot subtracted from this figure. The resulting value is taken as the zone of inhibition.
- 10 (vii) All experiments were carried out a minimum of three times for each strain-pathogen combination.

RESULTS

Anti-Campylobacter Potential of Probiotic Strains

15 Following incubation of the potential probiotic strains with campylobacter jejuni the zones of inhibition were determined for each strain (see Table 3 below).

20 Table 3

Probiotic Strain	Average Inhibition Zone (mm)
<i>L. acidophilus</i>	19.3
<i>L. ruminus</i>	16.3
<i>L. reuteri</i>	5.3
<i>L. murinus</i>	9.3
<i>L. mucosae</i>	2.7
<i>L. casei</i>	21.3

DISCUSSION

The anti-*Campylobacter* activity of the strains is clearly demonstrated.


**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

Mars Incorporated
6885 Elm Street
Virginia 22101
USA

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITARY AUTHORITY
identified at the bottom of this page

**NAME AND ADDRESS
OF DEPOSITOR**

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Lactobacillus acidophilus</i> WAL ML1	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: NCIMB 41117
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input checked="" type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 10 October 2001 (date of the original deposit) ¹	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: NCIMB Ltd., Address: 13 St Machar Drive, Aberdeen, AB24 3RY, Scotland.	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Date: 13 November 2001

¹ Where Rule 6/4(d) applies, such date is the date on which the status of International Depositary Authority was acquired.

Applicant's or agent's file reference number	P33587WO/TF	International application No.
--	-------------	-------------------------------

INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>7</u> , line <u>18</u> and on page 11, line 6	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution NCIMB Ltd	
Address of depositary institution (including postal code and country) 23 St Machar Drive Aberdeen AB24 3RY Scotland	
Date of deposit 10 October 2001	Accession Number NCIMB 41117
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
In respect of all designated States to which such action is possible and to the extent that it is legally permissible under the law of the designated State, it is requested that a sample of the deposited biological material be made available only by the issue thereof to an independent expert, in accordance with the relevant patent legislation, e.g. EPC Rule 28(4), UK Patent Rules 1995, Schedule 2, Paragraph 3, Australian Regulation 3.25(3) and generally similar provisions mutatis mutandis for any other designated State.	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only	For International Bureau use only
<input type="checkbox"/> This sheet was received with the international application	<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Claims

1. Use of a probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal *Campylobacter* infection, in a mammalian animal.
5
2. Use, as claimed in claim 1, wherein the probiotic microorganism is *Lactobacillus*.
- 10 3. Use, as claimed in claim 2, wherein the probiotic microorganism is *Lactobacillus acidophilus*.
4. Use, as claimed in any one of claims 1 to 3, wherein the *Campylobacter* is *Campylobacter jejuni*.
15
5. Use, as claimed in any one of claims 1 to 4, wherein the mammalian animal is a dog, cat or a human.
6. Use, as claimed in any one of claims 1 to 5, wherein the composition is a foodstuff.
20
7. Use, as claimed in claim 6, wherein the foodstuff is a dry pet food.
8. A method for the prevention or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal, the method comprising the administration of a probiotic microorganism to said animal.
25
9. A method, as claimed in claim 8, wherein the probiotic microorganism is comprised in a composition.

10. A method as claimed in claim 9, wherein the composition is a foodstuff.

11. A method, as claimed in claim 10, wherein the foodstuff is a dry pet
5 food.

12. A method, as claimed in any one of claims 8 to 10, wherein the
administration is by oral ingestion.

10 13. A method, as claimed in any one of claims 8 to 12, wherein the probiotic
microorganism is *Lactobacillus*.

14. A method, as claimed in claim 13, wherein the probiotic microorganism
is *Lactobacillus acidophilus*.

15

15. A method, as claimed in any one of claims 8 to 14, wherein the
Campylobacter infection is *Campylobacter jejuni*.

20

16. A method, as claimed in any one of claims 8 to 15, wherein the animal
is a cat, dog or a human.

17. A probiotic microorganism, for use in preventing or reducing
gastrointestinal *Campylobacter* infection in a mammalian animal.


25

18. A probiotic microorganism, as claimed in claim 17, which is comprised
in a composition.

19. Use of a probiotic microorganism, substantially as hereinbefore
described with reference to one or more of the examples.

20. A method for the preventing or reduction of gastrointestinal *Campylobacter* infection in a mammalian animal, substantially as hereinbefore described with reference to one or more of the examples.

Figure 1



INTERNATIONAL SEARCH REPORT

PCT/GB 03/02469

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A23K1/00 A23K1/18 A23L1/03 A61K35/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A23K A23L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, FSTA, CHEM ABS Data, CAB Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 02 058712 A (PROBIO HEALTH ;NAIDU A SATYANARAYAN (US)) 1 August 2002 (2002-08-01) page 11, line 20 - line 25 examples 1-4 claims 1,15-17	1, 2, 4-6, 8-10, 12, 13, 15-20
P, X	WO 02 43649 A (BUCHMAN GENADI ;OLSHENITSKY MARK (IL); BIO BALANCE CORP (US)) 6 June 2002 (2002-06-06) examples 5, 21 claims 2, 12-16, 21-23, 35, 40-44, 51-53, 55, 56	1, 2, 5, 6, 8-10, 12, 13, 16-18
X	WO 00 75284 A (BRAUN SERGEI ;BUCHMAN GENADI (IL); M G NOVOBIOTEC LTD (IL); OLSHEN) 14 December 2000 (2000-12-14) examples 5, 21 claims 1, 2, 11, 14-16, 19-23, 44	1, 5, 6, 8-10, 12, 16-18

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

16 September 2003

Date of mailing of the international search report

26/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dekeirel, M

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02469

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 29645 A (BIOFEED THAILAND CO LTD ;BUNKE PATRIK (SE); LINDBLOM RAGNVALD (TH)) 21 August 1997 (1997-08-21) claims 1,7,10,11,18 ---	1,5,6, 8-10,12, 16-18
Y	WO 97 35596 A (ABBOTT LAB) 2 October 1997 (1997-10-02) claims 1,2 ---	1-3, 5-14, 16-20
Y	WO 01 90311 A (PEREZ PABLO ;VON DER WEID THIERRY (AR); SCHIFFRIN EDUARDO (CH); NE) 29 November 2001 (2001-11-29) example 14 claims 1-13,26,30 ---	1-3, 5-14, 16-20
P,A	M. RINKINEN ET AL.: "Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal Enterococcus faecium colonization?" VETERINARY MICROBIOLOGY, vol. 92, no. 1-2, 2003, pages 111-119, XP001165730 AMSTERDAM, NL ISSN: 0378-1135 the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02469

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 8-16,20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02469

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02058712	A	01-08-2002	WO 02058712 A2	01-08-2002
			US 2002192202 A1	19-12-2002
WO 0243649	A	06-06-2002	AU 2100402 A	11-06-2002
			CA 2430292 A1	06-06-2002
			WO 0243649 A2	06-06-2002
			US 2002054866 A1	09-05-2002
			US 2002054867 A1	09-05-2002
			US 2002071835 A1	13-06-2002
			US 2002051772 A1	02-05-2002
			US 2002051773 A1	02-05-2002
			US 2002048567 A1	25-04-2002
			US 2002051774 A1	02-05-2002
			US 2002048568 A1	25-04-2002
			US 2002051775 A1	02-05-2002
			US 2002048569 A1	25-04-2002
			US 2002048570 A1	25-04-2002
			US 2002054868 A1	09-05-2002
			US 2002051776 A1	02-05-2002
WO 0075284	A	14-12-2000	AU 4947000 A	28-12-2000
			BR 0012104 A	12-03-2002
			CA 2375599 A1	14-12-2000
			EP 1185618 A1	13-03-2002
			WO 0075284 A1	14-12-2000
			JP 2003501080 T	14-01-2003
			US 2001001711 A1	24-05-2001
			US 2002054866 A1	09-05-2002
			US 2002054867 A1	09-05-2002
			US 2002071835 A1	13-06-2002
			US 2002051772 A1	02-05-2002
			US 2002051773 A1	02-05-2002
			US 2002048567 A1	25-04-2002
			US 2002051774 A1	02-05-2002
			US 2002048568 A1	25-04-2002
			US 2002051775 A1	02-05-2002
			US 2002048569 A1	25-04-2002
			US 2002048570 A1	25-04-2002
			US 2002054868 A1	09-05-2002
			US 2002051776 A1	02-05-2002
WO 9729645	A	21-08-1997	SE 510498 C2	31-05-1999
			AT 234019 T	15-03-2003
			AU 721811 B2	13-07-2000
			AU 1819097 A	02-09-1997
			BR 9707510 A	27-07-1999
			CA 2245964 A1	21-08-1997
			CN 1225556 A	11-08-1999
			DE 69719735 D1	17-04-2003
			EP 0881886 A1	09-12-1998
			JP 2001500364 T	16-01-2001
			NZ 330906 A	28-01-2000
			SE 9600568 A	22-08-1997
			WO 9729645 A1	21-08-1997
WO 9735596	A	02-10-1997	US 5902578 A	11-05-1999
			WO 9735596 A1	02-10-1997

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02469

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0190311	A	29-11-2001	AU 7843201 A	03-12-2001
			BR 0111275 A	10-06-2003
			CA 2409286 A1	29-11-2001
			WO 0190311 A1	29-11-2001
			EP 1290136 A1	12-03-2003
			NO 20025528 A	18-12-2002
